In today’s recent session, 0.58 million shares of the Bioline Rx Ltd ADR (NASDAQ:BLRX) have been traded, and its beta is 1.44. Most recently the company’s share price was $0.22, and it changed around $0.0 or -1.85% from the last close, which brings the market valuation of the company to $19.38M. BLRX at last check was trading at a discount to its 52-week high of $1.64, offering almost -645.45% off that amount. The share price’s 52-week low was $0.19, which indicates that the recent value has risen by an impressive 13.64% since then. We note from Bioline Rx Ltd ADR’s average daily trading volume that its 10-day average is 1.25 million shares, with the 3-month average coming to 1.08 million.
Bioline Rx Ltd ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended BLRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Bioline Rx Ltd ADR is expected to report earnings per share of 0.0 for the current quarter.
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Instantly BLRX has been showing red trend so far today with a performance of -1.85% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.2568 on recent trading dayincreased the stock’s daily price by 14.33%. The company’s shares are currently down -86.15% year-to-date, but still up 7.14% over the last five days. On the other hand, Bioline Rx Ltd ADR (NASDAQ:BLRX) is -24.22% down in the 30-day period. We can see from the shorts that 1.06 million shares have been sold at a short interest cover period of 2.39 day(s).
Bioline Rx Ltd ADR (BLRX) estimates and forecasts
Bioline Rx Ltd ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -61.16 percent over the past six months and at a 84.04% annual growth rate that is well above the industry average of 16.60%. The year-over-year growth rate is expected to be 419.01%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 7.72M in revenue for the current quarter. 1 analysts expect Bioline Rx Ltd ADR to make 792k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 4.8M and 6.86M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 60.80%. Forecasts for the next quarter put sales growth at -88.45%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.53%.
Bioline Rx Ltd ADR (NASDAQ:BLRX)’s Major holders
CVI HOLDINGS, LLC, with 1.126% or 0.82 million shares worth $0.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
